A wide range of toxicity test methods is used or is being developed for assessing the impact of endocrine-active compounds (EACs) on human health. Interpretation of these data and their quantitative use in human and ecologic risk assessment will be enhanced by the availability of mechanistically based dose-response (MBDR) 
The potential for various compounds to alter endocrine system function has received increasing public attention in the United States [e.g., Food Quality Protection Act, 1996 (1) , Safe Drinking Water Act Amendments of 1996 (2) ] and in other countries throughout the world. The recognition of this potential toxicity has led to debate about the ability of current testing methods to identify endocrine system effects throughout the full gamut of life stages. New screening assays and test protocols for reproductive and developmental toxicity have been developed and others are currently being evaluated (3) . In addition, a large number of new mechanistic test systems have been developed to evaluate interactions of endocrine-related compounds with specific hormone receptors. Together, these efforts will provide more comprehensive characterization of the potential hazards posed by exposure to these compounds. Coordinate with development of these new tools for hazard identification and new mechanistic tests is a need to create a set of refined dose-response assessment tools that use as much of this new data as possible (4) .
A workshop was held in May 1998 in which several subgroups focused on approaches for characterizing the effects of endocrine-active compounds (EACs) on human health at environmental exposure levels. One work group addressed issues related to development of mechanistically based dose-response (MBDR) models for EACs, emphasizing the potential role of mechanistic models in improving the scientific foundations of dose-response assessments for EACs. This report is the product of that work group.
Dose-Response Models
Currently, default dose-response assessment approaches differ for cancer and noncancer end points. Default carcinogen risk assessments assume that all doses of a carcinogenic compound carry some degree of risk (5) . Noncancer end points, including reproductive and developmental toxicity, have traditionally been regulated by assuming that these responses have a threshold. No observed adverse effect levels obtained from toxicity tests are adjusted by the application of uncertainty factors to derive reference doses or reference concentrations. The reference concentration methodology (6) for inhaled compounds includes defaults to calculate doses of inhaled compounds in specific regions of the respiratory tract. The newly proposed U.S. Environmental Protection Agency guidelines for carcinogen risk assessment emphasize the role of mode of action and tissue dosimetry (i.e., mechanistic data) in supporting departure from the linear cancer defaults. Consideration of both dosimetry and mode of action is essential in producing dose-response assessments that make maximal use ofavailable data and reduce uncertainties.
Quantitative dose-response models for toxicology relate adverse response outcome with exposure duration and intensity. These include empirical models that derive model parameters from fitting response data, models that incorporate limited mechanistic information, and finally, models that include exposure, dosimetry, tissue interactions, mode of action, and biologic responses in an integrated and more quantitative fashion. These latter models, explicitly incorporating mode of action and tissue dosimetry data, are referred to here as MBDR models. This summary of the dose-response work group provides background information regarding mechanistic models for EACs. It stresses the potential for these models to improve the precision of risk estimates below the range of sensitivity in current test methods (usually at the 5-10% incidence levels or at the 5-10% increase in a continuous measure of response) and to reduce uncertainties in risk assessments with EACs.
Empirical Dose-Response Models in Risk Assessment
Parameters derived from fitting empirical models to response data do not necessarily have specific biologic meaning or bear oneto-one relationships with particular biochemical or molecular parameters. Nonetheless, these empirical approaches are still important for assessing the range of response behaviors associated with exposure to these compounds (7) Endocrine systems and the impact of EACs on these systems appear to be readily amenable to MBDR modeling techniques. Much is known about the regulation of organ system function by natural hormones and about the interactions among various endocrine systems. This body of information can be combined with data on the perturbations of the endocrine system by specific classes of EACs to develop comprehensive and testable hypotheses. It is important to realize that these organized mechanistic models are a first-step hypothesis compilation. Optimally, these models should be used in experimental design in confirming or refuting the original hypothesis and for risk assessments based on the most plausible prevailing perception of modes of action. To accumulate appropriate data for improving the biologic basis of risk assessment with these EACs, special effort is necessary to develop protocols that simultaneously fulfill specific data needs for modeling and specific data needs for regulatory testing requirements.
Model Evaluation
The ability to organize and explain a broad array of diverse scientific findings is a primary goal of mechanistic modeling and is a key component for achieving broad scientific acceptance. A difficulty in gaining acceptance for these models occurs because of the very requirement that the models organize and integrate such a wide variety of experimental data. These ambitious structures may adequately describe the majority of studies but fail to match all observed results. It will be necessary to use a broad array of scientific evidence in characterizing and assessing the success of mechanistic models. The degree of emphasis to be placed on particular studies and the congruence of the model with the observed results will depend on both statistical issues and scientific judgment.
In many situations, it has been difficult to characterize how scientific judgment affects a regulatory decision because of the inability to express quantitatively the different risk estimates derived from differing assumptions regarding modes of action for xenobiotics. MBDR modeling uses diverse expertise to determine key biologic aspects of a model such as causal linkages between exposure changes and biologic effect. The explicit articulation of the mechanistic assumptions in these models shows their impact on the risk predictions. Thus, the process of risk assessment becomes more transparent (objective) and the ability to test these assumptions (challenging the model and/or validating its use) is greatly enhanced. The integration and analysis of hypotheses can provide a more explicit incorporation of scientific judgment into the process of evaluating the impact of specific mechanistic assumptions in risk assessments. The coupling of modeling results with elicitation of expert judgment has been considered a potential tool for achieving consensus in the use of mechanistic data and mechanistic models in risk assessment.
Mechanistic models, by their nature, attempt to describe in mathematical detail the processes involved in generating an adverse health effect from an environmental exposure. This has several clear advantages. First, when data are available on interindividual variation in response to any element of the process, this information can be directly incorporated into the use of the model for prediction using various population-oriented methods (19, 20 (25) . Carefully designed experiments and quantitative organization of the experimental data into a model should provide a more precise determination of the expected risks at different exposure levels. More generally, the development of mechanistic models can actually provide support for the relationship between responses and biomarkers at most levels of exposure.
Mechanistic modeling has other uses in addition to dose-response assessment. These models have been used to identify data gaps in our understanding of the toxicity of EACs and to identify key experiments to fill these gaps. In addition, by locating the critical elements governing the potential potency of an agent for a given effect, mechanistic modeling aids in identifying useful short-term, cost-effective testing strategies that directly contribute to the prediction of risks and strengthen the level of evidence needed to determine if a hazard exists. Optimally, several mechanistic models with differing underlying biologic mechanisms can be compared against various data sets to discriminate between competing mechanisms (25) . Experimental simulations with these competing models prior to acquisition of new data can identify the parameters with the greatest impact on model predictions. These parameters should be investigated initially to provide the greatest ability to discriminate between competing hypotheses. With EACs, this could involve comparing models, assuming receptor agonist activity, antagonist activity, or mixed activities before deciding on a specific experimental design to test the predictions.
Additionally, mechanistic models offer a logical framework in which to link exposure assessment and dose-response modeling. Extrapolation issues, when properly considered prior to developing a mechanistic model, can be more readily addressed. These include cross-species, cross-organ, cross-route, and cross-compound extrapolations. Specific data will be required for these model extrapolations; however, the amount of experimentation should be considerably less than required in the initial model development. Furthermore, issues associated with exposure to multiple agents working additively or synergistically can be addressed through model simulations that are followed by targeted experimentation to verify and/or refine these assumptions.
Other uses are in improving design of toxicity tests and creating modules useful for multiple chemicals. Regulatory agencies require that the chemical industry generate specific types of data on many compounds. Mechanistic models could greatly improve the value of these mandated toxicity testing results for risk assessment. This interaction, however, would only be possible if there were more flexibility in establishing protocols for toxicity testing. In addition, experimentation with prototype endogenous hormones (e.g., estradiol, testosterone) could provide information helpful in predicting the response to many other compounds with similar activities. Such generic, natural hormone models would include modules containing pharmacokinetics, receptor interaction, and tissueresponse portions. This information would be important for future studies with agonist/ antagonists of these native hormones.
Regulatory Acceptance
There is a degree of skepticism about the willingness of regulatory bodies to make decisions based on mechanistic models. Sometimes these concerns are caused by the unfamiliarity of regulators and many research scientists with these modeling techniques. It deserves emphasis that regulatory acceptance of MBDR models should be secondary, following broader acceptance of these techniques by the scientific community.
Within the regulatory structures, there is appreciation that current risk assessments have many uncertainties. These uncertainties often lead to 
Comparisons with Contemporary Approaches
In their applications to risk assessment, MBDR models should be compared and contrasted with the current default assumptions. The hurdle for application of mechanistic models and mechanistic data should not be set so high as to disqualify all but the most sophisticated and detailed of these models from application in risk assessments. Clearly, the utility of any quantitative model will be derived from a clear articulation of the reasons for constructing the model and the range of detail that is successfully captured in the model structure. The level of biologic detail in mechanistic models varies depending on the present state of knowledge of the normal biology and for the biology of specific EACs. Although it is a laudable goal to include all of the details of the expected biologic interactions, this level of detail cannot be provided at this time or in the foreseeable future. Hence, procedures must be in place to accept MBDR models as a means of improving risk assessments as part of a reiterative hypothesis-generating process, where continuing changes in these models may occur as (26, 27) . Modeling studies with other endocrine systems include androgen control of spermatogenesis (4) and thyroid hormone-mediated control processes (28 
Abbreviations: ADME, absorption, distribution, metabolism, and excretion; AhR, arylhydrocarbon receptor; AR, androgen receptor; CFD, computational fluid dynamics; EGF, epidermal growth factor; ER, estrogen receptor; E2, 17f-estradiol; FSH, follicular-stimulating hormone; GSH, glutathione; GST, glutathione S-transferase; LH, luteinizing hormone; LMS, linearized multistage; NIEHS, National Institute of Environmental Health Sciences; PBPK, physiologically based pharmacokinetics; PK, pharmacokinetics; SAR, structure-activity relationship; TCDD, tetrachlorodibenzo-p-dioxin; QSAR, quantitative structure-activity relationship; T, testosterone; TRH, thyroid-releasing hormone; TSH, thyroid-stimulating hormone; T3, triiodothyronine; T4, tetraiodothyronine. (40) .
Low-Dose Extrapolations with Endocrine-Active Compounds
The default position in noncancer risk assessments assumes a threshold, i.e., a dose below which there are negligible risks. A combination of empirical modeling and mechanistic data has been marshaled to suggest that there are certain developmental end points for which thresholds are unlikely to occur and others for which thresholds would not be at all unexpected (41) . There do appear to be situations in which it would be realistic to consider that there is a continuum of responses (i.e., no threshold dose for the observed effects) for added hormone agonists. For instance, when the natural outcome in adult reproductive system structure and function is determined by the in utero exposures to natural hormones, the addition of exogenous agonists should cause alterations in the response incidence. This expectation is consistent with additivity to background and with results of studies of the effect of uterine position on adult reproductive system parameters in rodent species (42) . The influence of processes without clear thresholds for risk assessment must still consider the severity (adversity) of the responses. Some effects, such as prostate size, represent changes in specific phenotypic characteristics that are themselves variable in the adult population. Risk assessment for these end points will revolve around definitions of adversity. The issues surrounding altered distribution of normal characteristics in the population are complex, requiring both technical input about adversity and public policy input on the level of tolerance for changes in these distributions by the public.
Several end points for which thresholds are uncertain were discussed in our deliberations. These responses included changes in androgen receptor number and prostate weight in adult male mice following in utero estrogen exposures (42) and turtle sex ratios following egg painting with estrogens (43, 44) . Other examples were also discussed, including fertility in a continuous breeding study in females exposed to DES in utero (45) and vaginal threads in female mice exposed to dioxin in utero (46) . Although these effects appear consistent with absence of threshold, they have not been examined statistically to determine the minimal threshold that would be consistent with the data. Statistical analyses of this kind would be informative and should be performed routinely.
Some of the molecular characteristics of gene transcriptional control by hormones and their receptors are expected to give rise to highly nonlinear dose-response characteristics due to positive feedback loops, receptor autoregulation, phosphorylation cascades, and control of enzymes involved in synthesis of high-affinity ligands (47) . These molecular behaviors can give rise to biologic switches, i.e., to the ability to abruptly change from one biologic condition to another over a very small change in ligand concentration. Examples appear to include estrogen receptor autoregulation during vitellogenesis in some fish and frog species (48) and thyroid hormone receptor upregulation in frog tadpoles during metamorphosis (49) . Highly nonlinear effects were also reported in progesterone-mediated maturation of Xenopus oocytes, a response mediated via mitogenicactivated protein kinase (50) . Many of these nonlinear switching mechanisms are expected to produce nonlinear dose-response curves for the action of native ligands. However, the dose response for effects of exogenous compounds, even when biologic switches are present, still depends on the combination of effects of the native ligand and perturbations of the EAC on the specific biologic effect.
Another aspect of the debate surrounding endocrine-active compounds is the concept of pharmacokinetic thresholds. Even (37) . Although less effort has been focused on mechanistic models of endocrine system function, a number of first-generation models have been published in recent years (4, (27) (28) (29) 
